logo-loader
viewAmphion Innovations PLC

Amphion Innovations' associate agrees deal for new antibiotic ahead of AIM float

drug_research_350_54bcb4ab28544.jpg

Motif BioSciences has agreed the acquisition of a new clinical treatment for MRSA and other drug-resistant bacteria as it gears up to list on AIM.

Antibody specialist Motif is 32% owned by intellectual property group Amphion Innovations (LON:AMP).

Once it completes its initial public offering (IPO), Motif will merge with the private company that owns the intellectual property and world-wide rights to the clinical stage antibiotic.

Phase III trials are scheduled to start this year in two serious hospital-acquired infections.

A condition of the merger is that Motif completes its AIM float before the end of March. Ahead of that Motif has completed a pre-IPO AIM financing of £470,000 of convertible promissory notes.

Richard Morgan, Amphion’s chief executive, said: "Resistance to antibiotics is a major global public-health crisis.

"The most urgent need for novel antibiotics effective against multi-drug resistant bacteria is in the hospital setting where patients often succumb to serious, life-threatening infections that require immediate treatment with the best available antibiotic.

"The acquisition of this clinical stage antibiotic is a game changer for Motif.  As a result of change in the regulatory environment geared to encourage new antibiotics, we believe we have identified the right course for regulatory approval.

“Motif's upcoming IPO will fund this exciting plan and we believe will generate and return value to both Motif and Amphion shareholders alike."

Quick facts: Amphion Innovations PLC

Price: 0.15 GBX

AIM:AMP
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amphion Innovations hails favourable court ruling

Richard Morgan, chief executive of Amphion Innovations (LON:AMP), explains the ins and outs of the ruling it has received in a US federal court relating to its patented intellectual property. He tells Proactive Investors that the company has been striving to protect a software patent related...

on 04/14/2014

2 min read